A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer

A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer

Abstract Background We developed and refined an S-1 dosage formula based on renal function, sex, and body surface area (BSA) to achieve the target area under the concentration–time curve of 5-fluorouracil in two prospective pharmacokinetic studies. The clinical validity of the refined formula (BBT f...

Full description

Saved in:
Bibliographic Details
Main Authors: Keisuke Baba, Nobumi Suzuki, Chiyo K. Imamura, Eisuke Booka, Masashi Takeuchi, Daisuke Takahari, Takeshi Kawakami, Hirofumi Kawakubo, Chiyoe Kitagawa, Yoshiyasu Kono, Keiji Ogura, Yosuke Kito, Kei Saito, Shinzo Yamamoto, Hiroya Takeuchi, Toshihiro Kudo, Takuya Tsunoda, Takuro Mizukami, Toshifumi Yamaguchi, Hirokazu Shoji, Kanako Saito, Kenro Tanoue, Eishi Baba, Kengo Nagashima, Narikazu Boku
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Cancer
Subjects:
Advanced gastric cancer
Dosage formula
Nivolumab
S- 1
Oxaliplatin
Online Access:https://doi.org/10.1186/s12885-025-14084-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14084-1

Similar Items